Pierre Fabre Cashes The AbCheck: Antibody Deal Expands After Initial Success
This article was originally published in The Pink Sheet Daily
Executive Summary
Decision by France’s third-largest drug maker to make AbCheck its main provider of antibody therapies will make Affimed’s Czech biotech profitable and better able to invest in rabbits.